U2AF1与EZH2突变与骨髓增生异常综合征中的非免疫性溶血性贫血相关
该研究以血清触珠蛋白<10 mg/dL作为血管内溶血替代标志物,在519例骨髓增生异常综合征(MDS)患者中评估溶血的发生率、基线特征、分子特征及对结局的影响。10%的患者存在溶血,其中仅13%抗人球蛋白试验(Coombs)阳性,提示溶血多为非免疫介导。溶血组U2AF1和EZH2热点突变更常见(P<.05),且低危MDS溶血患者生存趋势更差,对红系造血刺激剂(ESA)反应率降低、对低甲基化药物(HMA)反应率升高。
要点
- 519例MDS患者中10%存在溶血,仅13%的溶血患者Coombs阳性。
- 溶血组U2AF1和EZH2热点突变更常见(P<.05),U2AF1突变占溶血组30%且几乎均为S34热点。
- 低危MDS溶血患者生存趋势更差,溶血组对ESA反应率降低、对HMA反应率升高。
核心结论
- MDS中的溶血大多为非免疫介导,U2AF1和EZH2热点突变与溶血相关(P<.05)。
- 低危MDS溶血患者生存趋势更差,溶血组对ESA反应率降低、对HMA反应率升高。
研究设计与样本
- 研究纳入519例MDS患者,以基线血清触珠蛋白<10 mg/dL作为血管内溶血的替代标志物。
- 研究描述溶血患病率、基线特征、分子特征及对结局的影响。
主要发现
- 519例患者中10%存在溶血,溶血组与非溶血组基线特征相似。
- 溶血患者中仅13%为Coombs阳性。
- 低危MDS溶血患者生存趋势更差。
- 溶血组对ESA反应率降低、对HMA反应率升高。
- U2AF1和EZH2热点突变在溶血组更常见(P<.05);U2AF1突变见于30%的溶血患者,且几乎均位于S34热点。
关键数值与推荐
- 基线血清触珠蛋白<10 mg/dL作为血管内溶血的替代标志物。
- U2AF1和EZH2热点突变在溶血组更常见(P<.05)。
- 溶血组中U2AF1突变占30%,几乎均位于S34热点。
- 溶血患者中Coombs阳性者占13%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemolysis is a well-recognized but poorly characterized phenomenon in a subset of patients with myelodysplastic syndromes (MDS). Its pathobiological basis seems to underpin a nonimmune etiology whose clinical significance has not been adequately characterized. Hemolysis in MDS is often attributed to either ineffective intramedullary erythropoiesis or acquired hemoglobinopathies and red blood cell (RBC) membrane defects. These heterogeneous processes have not been associated with specific genetic subsets of the disease. We aimed to describe the prevalence of hemolysis among patients with MDS, their baseline characteristics, molecular features, and resulting impact on outcomes. We considered baseline serum haptoglobin <10 mg/dL a surrogate marker for intravascular hemolysis. Among 519 patients, 10% had hemolysis. The baseline characteristics were similar among both groups. Only 13% of patients with hemolysis were Coombs-positive, suggesting that hemolysis in MDS is largely not immune-mediated. Inferior survival trends were observed among lower-risk patients with MDS undergoing hemolysis. Decreased response rates to erythropoiesis-stimulating agents (ESA) and higher responses to hypomethylating agents (HMA) were also observed in the hemolysis group. U2AF1 and EZH2 hotspot mutations were more prevalent among those undergoing hemolysis (P < .05). U2AF1 mutations were observed in 30% of patients with hemolysis and occurred almost exclusively at the S34 hotspot. Somatic mutations encoding splicing factors may affect erythrocyte membrane components, biochemical properties, and RBC metabolic function, which underpin the development of atypical clones from erythroid precursors in MDS presenting with hemolysis. Future studies will explore the contribution of altered splicing to the development of acquired hemoglobinopathies.
引用
- Komrokji R, Aguirre LE, Al Ali N, et al. U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes. Blood Adv. 2023. PMID: 36129843. doi:10.1182/bloodadvances.2022007504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。